logo

For the Inventor, By the Inventor

Kanazawa, Japan

Yukihiko Kameda

USPTO Granted Patents = 11

Average Co-Inventor Count = 2.8

ph-index = 6

Forward Citations = 89(Granted Patents)


Location History:

  • Toyonaka, JA (1977)
  • Osaka, JA (1977)
  • Kanazawa, JA (1978)
  • Kanazawa, JP (1984 - 1990)

Company Filing History:

goldMedal11 out of 1,858 
 
Takeda Chemical Industries, Inc.
 patents

Years Active: 1977-1990

Loading Chart...
11 patents (USPTO):Explore Patents
1. 4946779 - Pseudo-aminosugars, their production and use (1990-08-07),
2. 4923975 - Valiolamine derivatives and production thereof (1990-05-08),
3. 4827036 - Pseudo-aminosugars, their production and use (1989-05-02),
4. 4803303 - N-substituted pseudo-aminosugars, their production and use (1989-02-07),
5. 4777294 - N-substituted pseudo-aminosugars, their production and use (1988-10-11),
6. 4701559 - N-substituted pseudo-aminosugars, their production and use (1987-10-20),
7. 4595678 - N-substituted pseudo-aminosugars and pharmaceutical compositions (1986-06-17),
8. 4486602 - Valienamine derivatives, their production and use (1984-12-04),
9. 4089947 - Antibiotic compositions containing validamycin compounds (1978-05-16),
10. 4065615 - Deoxyaminoglycoside antibiotic derivatives (1977-12-27),
11. 4011391 - Validamycin C, D, E and F antibiotics (1977-03-08),

Title: Innovations of Yukihiko Kameda

Introduction

Yukihiko Kameda is a prominent inventor based in Kanazawa, Japan. He has made significant contributions to the field of biochemistry, particularly in the development of novel compounds that have potential therapeutic applications. With a total of 11 patents to his name, Kameda's work focuses on addressing hyperglycemic symptoms and related disorders.

Latest Patents

Kameda's latest patents include the development of pseudo-aminosugars, specifically 5-amino-1-hydroxymethyl-1,2,3,4-cyclohexanetetrol. These compounds exhibit excellent .alpha.-glucosidase inhibitory activity, making them useful for managing hyperglycemic symptoms and various disorders caused by hyperglycemia. Another notable patent involves valiolamine derivatives, which are useful starting materials for creating more potent .alpha.-glucosidase inhibiting compounds. The production of these derivatives involves cultivating Streptomyces hygroscopics in a culture medium and recovering the resulting compounds from the culture broth.

Career Highlights

Kameda is currently associated with Takeda Chemical Industries, Inc., a leading pharmaceutical company. His work at Takeda has allowed him to focus on innovative research and development in the field of medicinal chemistry. His contributions have been instrumental in advancing the understanding of compounds that can aid in the treatment of metabolic disorders.

Collaborations

Kameda has collaborated with notable colleagues such as Satoshi Horii and Hiroshi Fukase. These collaborations have fostered a productive research environment, leading to the successful development of various innovative compounds.

Conclusion

Yukihiko Kameda's work exemplifies the impact of innovative research in the field of biochemistry. His patents and collaborations highlight his commitment to advancing therapeutic solutions for hyperglycemic conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…